News & Analysis as of

Center for Biologics Evaluation and Research (CBER) Center for Drug Evaluation and Research (CDER) Coronavirus/COVID-19

Wiley Rein LLP

The End of an Era: FDA Announces Disposition Plans for COVID-19 Related Guidance Documents

Wiley Rein LLP on

The COVID-19 pandemic presented the U.S. Food and Drug Administration (FDA or Agency) with a monumental task of shifting its operations and the way it approached the regulation of critical drugs, medical devices, and biologic...more

Locke Lord LLP

FDA Issues Guidance Detailing Current Policies on Facility Inspections and Product Approvals During the COVID-19 Pandemic

Locke Lord LLP on

The COVID-19 pandemic presents ongoing challenges to the pharmaceutical and biologics industries, where in-person inspection of facilities is often required for FDA approval of applications to market drug or biological...more

Foley & Lardner LLP

Improving 21st Century Cures Act: Personalized Medicine and COVID-19

Foley & Lardner LLP on

On April 27, 2020, Representatives Fred Upton (R-Michigan) and Diana DeGette (D-Colorado) released a “concept paper” to build on the success of the 21st Century Cures Act (Pub. L. 114-255) and improve the country’s...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide